Aft Pharmaceuticals, Ltd.
Clinical trials sponsored by Aft Pharmaceuticals, Ltd., explained in plain language.
-
One shot instead of two? new IV iron aims to simplify anemia treatment
Disease control Not yet recruitingThis phase 3 trial tests whether a single infusion of a new intravenous iron, Ferric Bepectate, can raise hemoglobin as effectively as two infusions of the current standard treatment (ferric carboxymaltose) in adults with iron deficiency anemia. About 1,366 participants will rece…
Phase: PHASE3 • Sponsor: AFT Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a cream make laser treatment for birthmarks more effective?
Disease control Not yet recruitingThis study tests whether a rapamycin cream, applied after laser treatment, can improve the appearance of port wine stain birthmarks in children aged 10 and under. Thirty participants will receive laser therapy plus either a low or high dose of the cream or a placebo cream for 12 …
Phase: PHASE2 • Sponsor: AFT Pharmaceuticals, Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo pill aims to ease teen surgery pain
Symptom relief Not yet recruitingThis study tests a new painkiller called Combogesic 325, which combines ibuprofen and acetaminophen, in 180 teens aged 12 to 17 recovering from orthopedic surgery. Participants receive either 2 or 3 tablets of Combogesic or plain acetaminophen every 6 hours for 24 hours. The goal…
Phase: PHASE3 • Sponsor: AFT Pharmaceuticals, Ltd. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
New IV pain relief combo for children enters final testing phase
Symptom relief Not yet recruitingThis study tests a new intravenous medicine called Combogesic IV, which combines two common pain relievers (acetaminophen and ibuprofen) into one infusion. It will involve 60 children aged 2 to 17 with acute pain who need IV pain relief. The goal is to see how the body processes …
Phase: PHASE3 • Sponsor: AFT Pharmaceuticals, Ltd. • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC